SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies
Paraskevi Sgourdou, Nicholas Vrettos, Kevt'her Hoxha…·Zissimos Mourelatos
This study introduces SilencioM, an siRNA-based therapeutic targeting MAPT, which reduces tau pathology in PS19 mice after a single injection.